CC
AGIO icon

Centiva Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Centiva Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-79,500
Closed -$2.16M – 1638
2025
Q4 		$2.16M Buy
79,500
+36,600
+85% +$1.28M 0.02% 425
2025
Q3 		$1.72M Buy
+42,900
New +$1.61M 0.02% 399

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Centiva Capital's AGIO Position: Q3 2025 in Review

Centiva Capital sold out of Agios Pharmaceuticals (AGIO) in Q3 2025, closing a stake of 15,040 shares — an estimated $566K sold.

Centiva Capital first reported a position in AGIO in Q1 2025 and held it in 2 quarters. The position peaked at $500K in Q2 2025. 221 funds tracked by Wall St. Rank hold AGIO as of Q3 2025.

  • Centiva Capital reported no remaining Agios Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 15,040 Agios Pharmaceuticals shares in Q3 2025, an estimated $566K.
  • Centiva Capital first reported a position in Agios Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Centiva Capital's Agios Pharmaceuticals position peaked at $500K in Q2 2025.
  • 221 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.